The Market for Colorectal Cancer
A durable and expanding global market driven by persistent unmet need in advanced disease.
Why Colorectal Cancer Remains a Major Focus
Colorectal cancer (CRC) is one of the most common cancers worldwide and remains a leading cause of cancer-related mortality. While treatment options have advanced, outcomes for patients with advanced disease remain limited—driving ongoing clinical urgency and sustained biopharmaceutical investment.
Barricade’s lead program, BT-1501, is being developed to target genetically defined colorectal cancer biology, advancing a precision approach for patients who need new options.
Colorectal Cancer: A Rising Global Burden
Global incidence and mortality are projected to increase through 2040.
CRC continues to grow in prevalence globally, with increasing incidence in younger populations and persistent mortality in advanced disease. This expanding burden reinforces the need for new treatment strategies.
A Multi-Billion-Dollar Global Market
Colorectal cancer remains a durable global market driven by metastatic disease and continued treatment innovation.
CRC represents a large, established oncology category with sustained demand. Market growth is supported by continued unmet needs in metastatic settings, ongoing combination strategies, and the search for targeted approaches in defined patient segments.
Market Sizing and Competitive Context
Leading therapies demonstrate the scale of the category and the opportunity for differentiated approaches.
CRC is an active and competitive therapeutic area, with multiple blockbuster products supporting a market that continues to attract innovation and capital. BT-1501 is being developed for APC-mutant colorectal cancer, a biologically defined segment within this broader landscape.
Building a Platform with Expansion Potential
BT-1501 is the lead program within Barricade’s TASIN platform. As clinical development advances, the company believes this targeted approach may support broader platform expansion across oncology and additional indications over time.